EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis

Aleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, Sabine Schaedelin, Johanna Oechtering iD, Lester Melie-Garcia, Alessandro Cagol iD, Riccardo Galbusera iD, Edoardo Galli, Jannis Müller iD, Sebastian Finkener, Patrice H Lalive und 34 weitere

Brain · 07.07.2026 · 149 (7) · 2295-2307

DOI: 10.1093/brain/awaf433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 14.11.2025. Verfasst von Aleksandra Maleska Maceski und 45 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Neurology, Departments of Biomedicine and Clinic…. Hauptthemen laut MEDLINE: Fingolimod Hydrochloride, Neurofilament Proteins, Glial Fibrillary Acidic Protein, Immunosuppressive Agents. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Progressive MS Alliance, Swiss MS Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In multiple sclerosis (MS) patients under therapy, the increase of serum glial fibrillary acidic protein (sGFAP) concentrations is associated with the course of ‘progression in absence of relapse’ (PIRA). While serum neurofilament light chain (sNfL) reflects both response as well as insufficient or lack of efficiency of disease-modifying therapies (DMT), the longitudinal course of sGFAP levels as a drug response marker for future PIRA in relation to specific types of DMT is less clear. We aimed to compare the predictive capacity of sGFAP and sNfL for PIRA and relapse activity and the longitudinal course in people with MS (PwMS) treated with fingolimod, based on Z scores derived from normative values. Overall, 420 PwMS under fingolimod treatment with follow-up of 9.1 years (interquartile range: 7.0–11.0) from the Swiss MS Cohort, contributing 2935 longitudinal serum samples, were included. A reference data set for sGFAP established from 4297 healthy controls across three European and North American cohorts was used to calculate Z scores. The longitudinal course and the predictive capacity of biomarkers for time to PIRA and relapse were assessed by Cox proportional hazards and linear mixed-effects models. In controls, sGFAP concentrations were 13.6% higher in females than males and increased exponentially with age. Altogether, 31.0% of PwMS experienced ≥1 PIRA event. Elevated sGFAP Z scores (>0.75) were associated with increased risk of PIRA [hazard ratio (HR): 1.64; 95% confidence interval (CI): 1.16–2.32; P = 0.006], while this was not the case for sNfL. Conversely, elevated sNfL predicted relapses (HR: 1.58; 95% CI: 1.13–2.23; P = 0.008), while sGFAP did not. Both biomarkers decreased under treatment: sGFAP by 0.19 Z score units (ZSU)/10 years (95% CI: −0.27 to −0.11; P < 0.001) and sNfL by 0.16 ZSU/10 years (95% CI: −0.27 to −0.06; P = 0.002). Serum GFAP remained elevated in PwMS with future PIRA events (estimate: 0.29; 95% CI: 0.07–0.50; P = 0.009); no such association was found for sNfL. Serum GFAP and sNfL Z scores provide complementary predictive capacity for PIRA and relapse risk. The decrease of sGFAP under fingolimod is a feature not observed with other types of DMT and may hint to a specific anti-neurodegenerative effect of Sphingosine-1-phosphate-receptor modulators on astrocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fingolimod HydrochlorideNeurofilament ProteinsGlial Fibrillary Acidic ProteinImmunosuppressive AgentsMultiple SclerosisHumansFemaleMaleDisease ProgressionAdultBiomarkersMiddle AgedRecurrenceLongitudinal StudiesPredictive Value of TestsCohort Studies

Stichwörter der Autor:innen

BiomarkerGFAP reference databaseprogression independent of relapse activity (PIRA)translational research

Substanzen

Fingolimod HydrochlorideNeurofilament ProteinsGlial Fibrillary Acidic Proteinneurofilament protein LBiomarkersImmunosuppressive AgentsGFAP protein, human

Autor:innen und Institutionen

  • Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Neurology, Departments of Biomedicine and Clinical Research, University Hospital and University Basel, Basel 4031, Swi…
  • Department of Clinical Research, University Hospital and University Basel, Basel 4031, Switzerland.
  • Translational Imaging in Neurology (ThINK) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital and University Basel, Basel 4031, Switzerland.
  • Dipartimento di Scienze della Salute, Università Degli Studi di Genova, Genova 16132, Italy.
  • Department of Neurology, Cantonal Hospital Aarau, Aarau 5000, Switzerland.
  • Department of Clinical Neurosciences, Division of Neurology, and Department of Medicine, Translational Biomarker Group, Geneva 1211, Switzerland.

ORCID-Profile: Johanna Oechtering, Alessandro Cagol, Riccardo Galbusera, Jannis Müller, Caroline Pot, Amandine Mathias, Lars G Hemkens, Patrick Roth, Marco Hermesdorf, David Conen, Cristina Granziera, Ahmed Abdelhak, David Leppert, Jens Kuhle

Förderung

  • Swiss National Science Foundation
  • Progressive MS Alliance
  • Swiss MS Society

Zitieren

APA

Maleska Maceski, A., Benkert, P., Einsiedler, M., Schaedelin, S., Oechtering, J., Melie-Garcia, L., Cagol, A., Galbusera, R., Galli, E., Müller, J., Finkener, S., Lalive, P. H., Uginet, M., Müller, S., Pot, C., Mathias, A., Du Pasquier, R., Hoepner, R., Chan, A., …, & Swiss Multiple Sclerosis Cohort (SMSC) (2026). GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis. Brain, 149(7), 2295-2307. https://doi.org/10.1093/brain/awaf433

Vancouver

Maleska Maceski A, Benkert P, Einsiedler M, Schaedelin S, Oechtering J, Melie-Garcia L, et al. GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis. Brain. 2026;149(7):2295-2307. doi:10.1093/brain/awaf433

BibTeX
@article{MaleskaMaceski2026,
  author = {Maleska Maceski, Aleksandra and Benkert, Pascal and Einsiedler, Maximilian and Schaedelin, Sabine and Oechtering, Johanna and Melie-Garcia, Lester and Cagol, Alessandro and Galbusera, Riccardo and Galli, Edoardo and Müller, Jannis and Finkener, Sebastian and Lalive, Patrice H and Uginet, Marjolaine and Müller, Stefanie and Pot, Caroline and Mathias, Amandine and Du Pasquier, Renaud and Hoepner, Robert and Chan, Andrew and Disanto, Giulio and Zecca, Chiara and D'Souza, Marcus and Hemkens, Lars G and Yaldizli, Özgür and Derfuss, Tobias and Roth, Patrick and Gobbi, Claudio and Brassat, David and Tackenberg, Björn and Pedotti, Rosetta and Raposo, Catarina and Oksenberg, Jorge and Green, Ari J and Wiendl, Heinz and Berger, Klaus and Hermesdorf, Marco and Piehl, Fredrik and Conen, David and Kappos, Ludwig and Khalil, Michael and Granziera, Cristina and Abdelhak, Ahmed and Leppert, David and Willemse, Eline A J and Kuhle, Jens and Swiss Multiple Sclerosis Cohort (SMSC), Swiss Multiple Sclerosis Cohort (SMSC)},
  title = {GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis},
  journal = {Brain},
  year = {2026},
  volume = {149},
  number = {7},
  pages = {2295--2307},
  doi = {10.1093/brain/awaf433}
}
Kostenlos starten →